Discover

IPHA
Innate Pharma S.A.
1.81
1 x 1.78
1 x 1.82
bid
ask
-
0.03
1.63%
1 @ 04:00 AM
1.90 +0.09 (4.97%)
Ytd3.43%
1y-2.16%
1.81
day range
1.89
1.17
52 week range
2.63
Open1.86Prev Close1.84Low1.81High1.89Mkt Cap169.96M
Vol8.04KAvg Vol73.77KEPS-0.63P/EN/AForward P/E4.67
Beta0.87Short Ratio5.63Inst. Own0.50%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-1350-d Avg1.70200-d Avg1.751yr Est7.41

IPHA News

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com
Innate Pharma Advances Lacutamab Phase 3 Trial And IPH4502 ADC Amid €25.4M Cash Runway Through Q3 20

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned

benzinga.com
Innate Pharma To Present Phase 2 MATISSE Prospectus Data On IPH5201 Combo In Resectable Lung Cancer

Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating I

benzinga.com
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) wit

Earnings Scheduled For March 26, 2026
benzinga.com
Earnings Scheduled For March 26, 2026

benzinga.com
Innate Pharma FY EPS $(0.64) Beats $(0.65) Estimate, Sales $10.483M Beat $7.230M Estimate

Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.64) per share which beat the analyst co

benzinga.com
BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8

BTIG analyst Jeet Mukherjee assumes Innate Pharma (NASDAQ:IPHA) with a Buy rating and announces

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com
Innate Pharma Reports €56.4M Cash And €2.3M Nine-Month Revenue As Lacutamab Advances Toward TELLOMAK

Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward P

benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com
Innate Pharma Gains FDA Clearance To Launch TELLOMAK 3 Phase 3 Trial Of Lacutamab In Sézary Syndrome

The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in pat

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
benzinga.com
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

benzinga.com
HC Wainwright & Co. Upgrades Innate Pharma to Buy, Announces $5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Innate Pharma (NASDAQ:IPHA) from

benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
benzinga.com
This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

Alphabet To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Thursday
benzinga.com
Alphabet To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Thursday

benzinga.com
Leerink Partners Downgrades Innate Pharma to Market Perform, Lowers Price Target to $2

Leerink Partners analyst Daina Graybosch downgrades Innate Pharma (NASDAQ:IPHA) from Outperform t

benzinga.com
HC Wainwright & Co. Downgrades Innate Pharma to Neutral

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Innate Pharma (NASDAQ:IPHA) fro

benzinga.com
Earnings Scheduled For September 17, 2025

benzinga.com
Innate Pharma H1 EPS $(0.28) Up From $(0.34) YoY, Sales $5.51M Down From $13.35M YoY

Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.28) per share. This is a 16.76 percent

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com
Earnings Scheduled For March 27, 2025

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

benzinga.com
Earnings Scheduled For March 21, 2024

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarte

benzinga.com
Earnings Scheduled For March 23, 2023

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earn

benzinga.com
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day S

Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Techn

benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the co

benzinga.com
Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket

Gainers AIM ImmunoTech Inc. (NYSE: AIM) shares rose 82.4% to $0.62 in pre-market trading. AIM Imm

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  During Monday's session, 402 companies made new 52-week lows.

benzinga.com
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts

Here's a roundup of top developments in the biotech space over the last 24 hours:

benzinga.com
89 Biggest Movers From Friday

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed

benzinga.com
Stocks That Hit 52-Week Lows On Monday

    On Monday, 524 stocks hit new 52-week lows.

benzinga.com
110 Biggest Movers From Yesterday

110 Biggest Movers From Yesterday

benzinga.com
95 Stocks Moving In Monday's Mid-Day Session

95 Stocks Moving In Monday's Mid-Day Session

benzinga.com
Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Monday

benzinga.com
Stocks That Hit 52-Week Lows On Friday

Stocks That Hit 52-Week Lows On Friday

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Thursday